Production of phospholipid antibodies in selected thrombophilic women differing in genotype at the 506 site of factor V

European Journal of Haematology

Volumn 61, Issue 1, 1998, Pages 21-26

  Bokarewa, Maria I ^a   Bremme, Katarina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Factor V; Lupus anticoagulant; Protein C; Prothrombin

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; GLUTAMINE; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOPHILIA;

EID: 0031842125     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01056.x     Document Type: Article

References (40)

1. McNAIL, PN, CHESTERMAN CN, KRILIS SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991: 49: 193-280.
2. LOVE PE, SANTORO SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990: 112: 682-698.
3. DAHLBÄCK B. New insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995: 74: 139-148.
4. BERTINA RM, REITSMA PH, ROSENDAAL FR, VANDENBROUKE JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995: 74: 447-453.
5. REES DC, Cox M, CLEGG JB. World distribution of factor V Leiden. Lancet 1995: 346: 1133-1134.
6. VANDENBROUCKE JP, KOSTER T, BRIET E, BERTINA RM, ROSENDAAL FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994: 344: 1453-1456.
7. RIDKER PM, HENNEKENS CH, LINDPAINTNER K, STAMPFER MJ, EISENBERG PR, MILETICH JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. NEJ Med 1995: 332: 912-917.
8. FINAZZI G, BRANCACCIO V, MOIA M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996: 100: 530-536.
9. GINSBERG KS, LIANG MH, NEWCOMER L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Int Med 1992: 117: 997-1002.
10. BOKAREWA MI, BREMME K, FALK G, STEN-LINDER M, EGBERG N, BLOMBÄCK M. Studies on phospholipid antibodies. APC resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995: 78: 193-200.
11. BOKAREWA MI, BLOMBÄCK M. Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis. Semin Hematol 1997: 34: 235-243.
12. KALAFATIS M, BERTINA RM, RAND MD, MANN K. Characterisation of the molecular defect in factor V R506Q. J Biol Chem 1995: 270: 4053-4057.
13. BERTINA RM, KOELEMAN BPC, KOSTER F, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994: 369: 64-67.
14. ZÖLLER B, SVENSSON P, HE X, DAHLBÄCK B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994: 94: 2521-2524.
15. CUMMING AM, TAIT RC, FILDES S, YOONG A, KEENAY S, HAY CR. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995: 90: 725-727.
16. 506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996: 92: 473-478.
17. OLIVIERI O. FRISO S, MANZATO F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995: 91: 465-470.
18. MARCINIAC E, ROMOND EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989: 74: 2426-2435.
19. BOKAREWA MI, BLOMBÄCK M, EGBERG N, ROSEN S. A new variant of interaction between phospholipid antibodies and protein C system. Blood Coag Fibrinol 1994: 5: 37-41.
20. HARRIS EN. The Second International Anticardiolipin Standardization Workshop. The Kingston antiphospholipid antibody study group. Am J Clin Path 1990: 94: 476-484.
21. PERTAIUOLO W, BOVILL E, HOAK J. The lupus anticoagulant stimulates the release of prostacyclin from human endothelial cells. Thromb Res 1988: 50: 847-855.
22. BRANCH DW, RODGERS GM. Induction of endothelial cell tissue factor activation by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstetr Gyn 1993: 168 (pt 1): 206-210.
23. CASCIOLA-ROSEN S, ROSEN A, PETRI M, SCHISSEL M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implication for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996: 93: 1624-1629.
24. STEGNAR M, BOZIC B, PETERNEL P, KVEDER T, VENE N, ROZMAN B. Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis. Thromb Res 1991: 63: 433-443.
25. KORDICH LC, FORESTIERO RR, BASILOTTA E, PORTERIE P, CARERRAS LO. Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant. Blood Coag Fibrinol 1992: 3: 765-771.
26. BORRELL M, SALA N, DE CASTELLARNAC C, LOPEZ S, GARI M, FONTCUBERTA J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the interaction of factor Va by activated protein C on human endothelial cells. Thromb Haemostas 1992: 68: 268-272.
27. MALIA RG, KICHEN S, GREAVES M, PRESTON FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990: 76: 101-107.
28. PÖTZSCH B, KAWAMURA H, PREISSNER KT, SCHMIDT M, SEELING C, MULLER-BERGHAUS G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995: 125: 56-65.
29. Lo SCL, SALEM HH, HOWARD MA, OLDMEADOW MJ, FIRKIN BG. Studies of natural anticoagulant properties and anticardiolipin antibodies in patients with lupus anticoagulant. Br J Haematol 1990: 76: 380-386.
30. PARKE AL, WEINSTEIN RE, BONA RD, MAIER DB, WALKER FJ. The trombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S. Am J Med 1992: 93: 49-56.
31. 506-Gln mutation. J Rheumatol 1995: 22: 125.
32. DIZON-TOWNSON D, HUTCHISON C, SILVER R, BRANCH DW, WARD K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with Antiphospholipid Syndrome. Thromb Haemostas 1995: 74: 1029-1031.
33. FIJNEER R, HORBACH DA, DONDERS RCJM, et al. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemostas 1996: 76: 514-517.
34. ROUBEY RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994: 84: 2854-2867.
35. HUNT JE, ADELSTEIN S, KRILIS SA. New basic aspects of the antiphospholipid syndrome. Clin Exp Rheumatol 1994: 12: 661-668.
36. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990: 87: 4120-4124.
37. BEVERS EM, GALLI M, BARBUI T, COMFURIUS S, ZWAAI. RFA. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid bound human prothrombin. Thromb Haemostas 1991: 66: 629-632.
38. 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994: 83: 2878-2892.
39. ARVIEUX J, DARNIGE L, CARON C, REBER G, BENSA JC, COLOMB MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulant. Thromb Haemostas 1995: 74: 1120-1125.
40. 2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemostas 1997: 78: 1008-1014.